1064O ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer (EOC): Final overall survival (OS) analysis
- Authors:
- AR Clamp, I McNeish, D Radice, R Lord, A Michael, A Cook, R Agarwal, A Walther, SP Blagden, D O'Donnell, JD Brenton, S Sundar, C Sessa, LR Murphy, F Schiavone, A Gentry-Maharaj, RS Kaplan, MK Parmar, JA Ledermann
- Journal:
- Annals of Oncology
- Citation info:
- 36:s712-s713
- Publication date:
- 1st Sep 2025
- Full text
- DOI